Juno Therapeutics, Inc. (JUNO) Upgraded to “Outperform” at Wedbush
Wedbush upgraded shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) from a neutral rating to an outperform rating in a research report report published on Tuesday. They currently have $42.00 price objective on the biopharmaceutical company’s stock.
Other equities research analysts also recently issued reports about the stock. Vetr raised shares of Juno Therapeutics to a buy rating in a report on Tuesday, May 23rd. BidaskClub raised shares of Juno Therapeutics from a hold rating to a buy rating in a report on Tuesday, June 20th. Zacks Investment Research downgraded shares of Juno Therapeutics from a buy rating to a hold rating in a report on Tuesday, May 2nd. BTIG Research downgraded shares of Juno Therapeutics from a neutral rating to a sell rating and increased their price target for the stock from $12.00 to $23.00 in a report on Tuesday, June 6th. Finally, FBR & Co reissued a hold rating on shares of Juno Therapeutics in a report on Thursday, May 18th. Two analysts have rated the stock with a sell rating, six have given a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has a consensus rating of Hold and an average target price of $31.86.
Shares of Juno Therapeutics (JUNO) opened at 43.81 on Tuesday. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $44.60. The company’s market cap is $4.60 billion. The company has a 50-day moving average of $28.62 and a 200-day moving average of $25.14. Juno Therapeutics also was the recipient of unusually large options trading activity on Tuesday. Investors purchased 6,838 put options on the company. This is an increase of 977% compared to the average volume of 635 put options.
Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. Juno Therapeutics had a negative return on equity of 27.10% and a negative net margin of 354.36%. The firm had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same period in the previous year, the company posted ($0.64) earnings per share. The company’s quarterly revenue was down 22.8% compared to the same quarter last year. Equities analysts forecast that Juno Therapeutics will post ($3.12) EPS for the current year.
In other Juno Therapeutics news, Director Anthony B. Evnin purchased 9,000 shares of Juno Therapeutics stock in a transaction on Tuesday, June 20th. The shares were acquired at an average cost of $24.40 per share, for a total transaction of $219,600.00. Following the completion of the transaction, the director now directly owns 66,301 shares of the company’s stock, valued at $1,617,744.40. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Richard Klausner sold 12,000 shares of the stock in a transaction that occurred on Monday, August 7th. The shares were sold at an average price of $30.34, for a total transaction of $364,080.00. Following the transaction, the director now owns 788,985 shares in the company, valued at $23,937,804.90. The disclosure for this sale can be found here. Insiders have sold 8,053,500 shares of company stock worth $217,594,440 over the last quarter. Company insiders own 15.26% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Teachers Advisors LLC boosted its position in shares of Juno Therapeutics by 12.3% in the fourth quarter. Teachers Advisors LLC now owns 60,834 shares of the biopharmaceutical company’s stock worth $1,147,000 after buying an additional 6,643 shares during the last quarter. Nisa Investment Advisors LLC acquired a new position in shares of Juno Therapeutics during the first quarter worth approximately $200,000. Wells Fargo & Company MN boosted its position in shares of Juno Therapeutics by 238.4% in the first quarter. Wells Fargo & Company MN now owns 121,392 shares of the biopharmaceutical company’s stock worth $2,693,000 after buying an additional 85,516 shares during the last quarter. Canada Pension Plan Investment Board boosted its position in shares of Juno Therapeutics by 111.2% in the first quarter. Canada Pension Plan Investment Board now owns 94,400 shares of the biopharmaceutical company’s stock worth $2,095,000 after buying an additional 49,700 shares during the last quarter. Finally, Great West Life Assurance Co. Can boosted its position in shares of Juno Therapeutics by 80.5% in the first quarter. Great West Life Assurance Co. Can now owns 8,518 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 3,800 shares during the last quarter. Institutional investors and hedge funds own 70.76% of the company’s stock.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.